GlassScriptPhysician profile
Kirollos E Zaki
NPI 1104270305
$473.94
in general payments reported to CMS, 2019-2025
8 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $110 · 2022: $47.55 · 2023: $23.02 · 2024: $138 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $117.15 | 2022-2024 | Farxiga, Lokelma |
| Veloxis Pharmaceuticals, INC. | $110.38 | 2020 | |
| Novo Nordisk INC | $70.85 | 2024-2025 | Ozempic, Rybelsus |
| Ardelyx, INC. | $64.25 | 2025 | Ibsrela |
| Scpharmaceuticals INC. | $36.93 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.64 | 2024 | Jardiance |
| Akebia Therapeutics INC | $24.58 | 2024 | Auryxia |
| Otsuka America Pharmaceutical, INC. | $24.16 | 2024 | Jynarque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirollos Zaki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.